证券代码：688238 证券简称：和元生物 公告编号：2025-036 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 100 | | --- | --- | | 普通股股东人数 | 100 | | 2、出席会议的股东所持有的表决权数量 | 176,805,041 | | 普通股股东所持有表决权数量 | 176,805,041 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 28.0505 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 28.0505 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长潘讴东先生主持，采用现场表决与 （一） 股东大会召开的时间：2025 年 5 月 8 日 （二） 股东大会召开的地点：上海市临港新片区沧海路 3888 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 和元生物技 ...

和元生物公告，股东华睿盛银及其一致行动人计划减持不超过649.04万股，占公司总股本的1%。减持 期间为2025年5月30日至2025年8月29日，减持方式为集中竞价和大宗交易。 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of He Yuan Biological Technology Co., Ltd., which focuses on gene therapy and related services [1][2] - As of the first quarter of 2025, the company reported a revenue of 52.85 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, representing a year-on-year decline of 41.04% [1] - The company's gross profit margin was reported at -36.44%, indicating challenges in profitability [1] Group 2 - He Yuan Biological has a current market capitalization of 3.816 billion yuan and a price-to-book ratio of 2.35 [1][2] - The company is among seven institutions holding shares, with a total of 83.47 million shares valued at approximately 459 million yuan [1] - The industry average price-to-earnings ratio (PE) is 38.66, while He Yuan Biological's trailing PE is -11.25, indicating a significant underperformance compared to industry peers [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of He Yuan Biological Technology Co., Ltd., a biotech company focused on gene therapy [1][2] - As of the first quarter of 2025, He Yuan reported a revenue of 52.85 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, representing a 41.04% decline compared to the previous year [1] - The company's gross profit margin was reported at -36.44%, indicating challenges in profitability [1] Group 2 - He Yuan's current stock price is 5.42 yuan, with a market capitalization of 3.518 billion yuan and a price-to-book ratio of 2.17 [1] - The company is among seven institutions holding shares, with a total of 83.47 million shares valued at 459 million yuan [1] - In comparison to industry averages, He Yuan's price-to-earnings ratio (TTM) is -10.37, while the industry average is 40.74 [2]

国泰海通证券股份有限公司 关于和元生物技术（上海）股份有限公司 2024 年度持续督导年度跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：和元生物 | | --- | --- | | 保荐代表人姓名：陈恒瑞、张子慧 | 被保荐公司代码：688238.SH | 重大事项提示 2024 年度，公司实现营业收入 24,814.92 万元，同比增长 21.16%，实现归属 于母公司所有者的净利润-32,181.30 万元，实现归属于母公司所有者的扣除非经 常性损益的净利润-33,591.24 万元，较上年同期下降。报告期内，公司 CDMO 业 务继续受宏观环境变化、产业状况、下游需求等因素影响，执行订单价格仍处于 较低水平，而公司临港产业基地一期已全面投产，产能释放需要时间，折旧摊销 成本、能耗成本、行政办公费用以及场地搬迁等原因导致运营成本费用同比大幅 增长，报告期内细胞和基因治疗 CDMO 业务营业毛利、净利润继续出现负值， 较上年度亏损增加。未来如果国内市场景气度回暖不及预期，生物医药投融资环 境持续低迷，下游 CGT CDMO 客户新药研发动力无法得到资金推动，而公司以 国内 CGT ...

Core Insights - The company has evolved from a small 12 square meter incubation base to a production platform of over 77,000 square meters in Lingang, becoming a pioneer in the cell and gene therapy (CGT) sector [2][4] - The chairman emphasizes the importance of perseverance and innovation in driving the company's growth and success in the CGT field [2][3] Company Development - The company started its journey in 2006, initially providing adenoviral vector services to research institutions and gradually expanding its operations [3] - The company has successfully transitioned from a small startup to a major player in the CGT industry, benefiting from a solid foundation laid in its early years [3][4] Capital Market Interaction - The company went public on the New Third Board in 2016, which provided sufficient funding to expand its capabilities in the gene therapy CDMO sector [4] - In 2022, the company successfully listed on the Sci-Tech Innovation Board, and by 2024, its Lingang base's first phase construction was completed and fully operational [4] Industry Trends - Cell and gene therapy is recognized as the "third revolution" in life sciences, with increasing applications in treating various diseases [5] - The company is focused on overcoming challenges in the CGT industry by enhancing its core technologies and expanding its intellectual property protection [5][6] Technological Advancements - The company aims to improve the development and production processes of gene therapy vectors, including the research of AAV viral vectors for rare diseases and the development of non-viral gene therapy vectors [5][6] - The company is investing in large-scale GMP production and quality control technologies to address bottlenecks in the CGT production process [6] Future Strategy - The company plans to leverage its Lingang base to provide comprehensive CRO/CDMO solutions, aiming to reduce costs and accelerate drug development [7][8] - Future initiatives include expanding into stem cell therapy and regenerative medicine, establishing a full-service capability from cell storage to clinical transformation [8] - The company is also looking to grow its CRO and CDMO services internationally, with potential mergers and collaborations to diversify its product offerings in cell and gene therapy [8]

股票简称：和元生物 股票代码：688238 2024 年年度股东大会 会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2025 年 5 月 和元生物技术（上海）股份有限公司 2024 年年度股东大会会议资料 和元生物技术（上海）股份有限公司 2024 年年度股东大会会议资料目录 | 2024 年年度股东大会会议须知 | 2 | | --- | --- | | 2024 年年度股东大会会议议程 | 4 | | 2024 年年度股东大会会议议案 | 6 | | 议案一、《关于<2024 | 年年度报告及摘要>的议案》 7 | | 议案二、《关于<2024 | 年度董事会工作报告>的议案》 8 | | 议案三、《关于<2024 | 年度监事会工作报告>的议案》 9 | | 议案四、《关于<2024 | 年度财务决算报告>的议案》 10 | | 议案五、《关于<2025 | 年度财务预算报告>的议案》 11 | | 议案六、《关于<2024 | 年度利润分配方案>的议案》 12 | | 议案七、《关于续聘 2025 | 年度审计机构的议案》 1 ...

近期和元生物(688238)发布2025年一季报，证券之星财报模型分析如下： 经营概况 近期，和元生物(688238)发布了2025年一季报。报告显示，公司一季度营业总收入为5284.77万元，同比 下降11.29%；归母净利润为-5947.73万元，同比下降41.04%；扣非净利润为-5959.27万元，同比下降 27.17%。 收入构成分析 从主营收入构成来看，细胞和基因治疗CRO业务收入为1,986.40万元，同比增长10.59%，保持稳定增 长；细胞和基因治疗CDMO业务收入为2,761.31万元，同比下降27.74%，主要由于报告期内在执行 CDMO订单的类型及不同CDMO项目推进情况的影响；其他主营业务收入为535.51万元，同比增长 60.26%。 财务指标分析 毛利率与净利率 一季度毛利率为-36.44%，同比减少73.17%；净利率为-112.61%，同比减少58.6%。这表明公司在成本控 制方面面临较大挑战。 三费分析 销售费用、管理费用、财务费用总计2932.12万元，三费占营收比为55.48%，同比增加8.34%。较高的三 费占比进一步压缩了公司的盈利空间。 现金流与负债 一季度每股经 ...

Core Viewpoint - The company reported a decline in total revenue for the first quarter of 2025, with specific segments showing varied performance, indicating challenges in the CDMO business while maintaining growth in CRO and other services [7][8]. Financial Performance - The company achieved total revenue of 52.84 million yuan, a decrease of 11.29% compared to the same period last year [7]. - Revenue from cell and gene therapy CRO services was 19.86 million yuan, reflecting a growth of 10.59% year-on-year [7]. - Revenue from cell and gene therapy CDMO services was 27.61 million yuan, down 27.74% year-on-year, primarily due to the types of CDMO orders executed and the progress of different projects [7]. - Other main business segments, including research reagents and cell storage services, generated revenue of 5.36 million yuan, an increase of 60.26% year-on-year [7]. Business Development - The company secured over 28 million yuan in new CDMO orders during the reporting period [7]. - It assisted clients in obtaining two IND approvals in the US and China, including one from the FDA, bringing the total to 46 approvals across multiple countries, with 13 from the FDA [7]. Intellectual Property - The company and its subsidiaries registered three new domestic trademarks and one copyright, and applied for two invention patents and six utility model patents during the reporting period [8]. - As of the end of the reporting period, the company held a total of 27 invention patents, 16 utility model patents, 2 design patents, 1 software copyright, 8 works copyrights, 65 domestic trademarks, and 4 international trademarks [8]. Share Buyback - On February 13, 2025, the company approved a share buyback plan to repurchase its A-shares using its own funds and a special loan for stock repurchase [9]. - As of April 10, 2025, the company completed the buyback of 18,726,690 shares, with a total expenditure of approximately 99.94 million yuan [10].

国泰海通证券股份有限公司 关于和元生物技术（上海）股份有限公司 2024 年度持续督导工作现场检查报告 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为和元 生物技术（上海）股份有限公司（以下简称"和元生物"或"公司"）首次公开 发行股票并在科创板上市的保荐人，根据《中华人民共和国公司法》《中华人民 共和国证券法》《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股 票上市规则》（以下简称"《上市规则》"）和《上海证券交易所上市公司自律监管 指引第 11 号——持续督导》等有关法律法规的规定，对公司 2024 年度（以下简 称"本持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关 情况报告如下： 一、本次现场检查的基本情况 陈恒瑞、张子慧 （三）现场检查时间 2025 年 4 月 10 日至 2025 年 4 月 17 日 （四）现场检查人员 陈恒瑞、张俊鑫 （五）现场检查内容 1 （一）保荐人 国泰海通证券股份有限公司 （二）保荐代表人 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交 ...